Koninklijke Philips (NYSE:PHG) Shares Sold by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC lowered its stake in shares of Koninklijke Philips (NYSE:PHG) by 9.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 54,701 shares of the technology company’s stock after selling 5,755 shares during the period. Schechter Investment Advisors LLC’s holdings in Koninklijke Philips were worth $1,276,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of PHG. FMR LLC increased its stake in shares of Koninklijke Philips by 1.7% in the 3rd quarter. FMR LLC now owns 9,516,906 shares of the technology company’s stock valued at $189,767,000 after purchasing an additional 155,055 shares in the last quarter. Wellington Management Group LLP grew its position in Koninklijke Philips by 16.7% in the first quarter. Wellington Management Group LLP now owns 8,245,236 shares of the technology company’s stock worth $251,727,000 after acquiring an additional 1,178,744 shares during the period. BlackRock Inc. grew its position in Koninklijke Philips by 0.6% in the second quarter. BlackRock Inc. now owns 6,671,419 shares of the technology company’s stock worth $144,703,000 after acquiring an additional 37,942 shares during the period. Morgan Stanley lifted its stake in Koninklijke Philips by 9.9% during the fourth quarter. Morgan Stanley now owns 3,351,702 shares of the technology company’s stock worth $50,242,000 after purchasing an additional 302,633 shares in the last quarter. Finally, Mondrian Investment Partners LTD lifted its stake in Koninklijke Philips by 19.6% during the second quarter. Mondrian Investment Partners LTD now owns 3,075,529 shares of the technology company’s stock worth $66,708,000 after purchasing an additional 504,869 shares in the last quarter. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Stock Performance

Shares of PHG stock opened at $20.32 on Thursday. The stock’s 50-day moving average is $21.00 and its two-hundred day moving average is $20.93. Koninklijke Philips has a 1 year low of $16.18 and a 1 year high of $24.27. The company has a quick ratio of 0.78, a current ratio of 1.20 and a debt-to-equity ratio of 0.58.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. Koninklijke Philips had a positive return on equity of 14.17% and a negative net margin of 2.53%. As a group, sell-side analysts forecast that Koninklijke Philips will post 1.52 earnings per share for the current year.

Analyst Ratings Changes

PHG has been the topic of several analyst reports. StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. BNP Paribas cut Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.